Tectonic Therapeutic (TECX) Income from Continuing Operations (2017 - 2026)
Tectonic Therapeutic (TECX) posted quarterly Income from Continuing Operations of 53803000.0 for Q1 2026, down 236.16% year-over-year from 39513468.32 in Q1 2025, and down 179.85% quarter-over-quarter from 19226000.0 in Q4 2025.
Tectonic Therapeutic (TECX) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Tectonic Therapeutic (TECX) has reported Income from Continuing Operations for 10 consecutive years, with 53803000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 236.16% year-over-year to 53803000.0; the TTM figure through Mar 2026 stood at 112048000.0 (down 99.14% YoY), while the FY2025 annual figure was 74151000.0, down 33.65% from the prior year.
- Income from Continuing Operations fell to 53803000.0 in Q1 2026 per TECX's latest filing, from 19226000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 9275000.0 in Q4 2023 and bottomed at 53803000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 20516000.0 across 5 years, with a median of 19035000.0 in 2025.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations surged 64.08% — and 2026, when it plunged 236.16%.
- Tectonic Therapeutic's Income from Continuing Operations stood at 25818000.0 in 2022, then soared by 64.08% to 9275000.0 in 2023, then dropped by 6.46% to 9874000.0 in 2024, then plunged by 94.71% to 19226000.0 in 2025, then plunged by 179.85% to 53803000.0 in 2026.
- Business Quant data shows TECX's Income from Continuing Operations at 53803000.0 in Q1 2026, 19226000.0 in Q4 2025, and 19035000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Tectonic Therapeutic | 671.50 Mn | 671.50 Mn | - | -22.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.29 Mn |
| Mar 31, 2026 | -53.80 Mn |
| Dec 31, 2025 | -19.23 Mn |
| Sep 30, 2025 | -19.04 Mn |
| Jun 30, 2025 | -19.98 Mn |
| Mar 31, 2025 | -16.01 Mn |
| Dec 31, 2024 | -9.87 Mn |
| Sep 30, 2024 | -17.72 Mn |
| Jun 30, 2024 | -12.67 Mn |
| Mar 31, 2024 | -13.23 Mn |
| Dec 31, 2023 | -9.28 Mn |
| Sep 30, 2023 | -11.09 Mn |
| Jun 30, 2023 | -10.64 Mn |
| Mar 31, 2023 | -25.97 Mn |
| Dec 31, 2022 | -25.82 Mn |
| Sep 30, 2022 | -24.02 Mn |
| Jun 30, 2022 | -29.31 Mn |
| Mar 31, 2022 | -31.12 Mn |
| Dec 31, 2021 | -28.41 Mn |
| Sep 30, 2021 | -32.62 Mn |